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ABSTRACT  
Objective: Study of Nimodipine, a calcium channel blocker was done on experiments involving tail suspension test (TST), elevated plus maze (EPM) 
test and Phenobarbitone induced sleeping time in Swiss albino mice.  
Methods: Nimodipine was given by intraperitoneal (i. p.) route in the dose of 2.5 & 5 mg/kg body wt respectively in albino mice of either sex (n=6) 
and effects were evaluated on (i) TST for antidepressant activity (ii) EPM for anti-anxiety and (iii) Loss of righting reflex for hypnotic activity and 
results were compared with the standard drugs like sertraline, diazepam and phenobarbitone respectively. Statistical analysis was done by ANOVA 
followed by Post hoc Tukey’s test using SPSS v.20.0 software.  
Results: Nimodipine at a dose of 2.5 mg/kg has shown moderate anti-anxiety and antidepressant activities compared to control with no changes in 
the activity of acute sertraline; however, the antidepressant activity of subacute sertraline (14 d treatment) was summed up by 2.5 mg/kg dose 
without any hypnosis. While at higher doses of 5 mg/kg depression, behavior (prolonged time of immobilization on TST) and sedation (prolonged 
phenobarbitone induced sleep time) were seen. 
Conclusion: Nimodipine has shown moderate antidepressant and anti-anxiety activities at low doses and can be used as add-on therapy to routine 
drugs with least of peripheral side effects. 
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INTRODUCTION 
Depression and morbid anxiety are the most common type of 
neurotic disorders which have affected the productivity of nations 
worldwide in terms of economic and manpower loss. Depression is 
characterized by severe negative and nihilistic thoughts (life is not 
worth living), the intense sadness of mood, loss of interest in routine 
work, low or high appetite, insomnia and severe suicidal tendency. 
Similarly, anxiety neurosis is accompanied by autonomic 
overactivity leading to tachycardia, tremors, sweating, and loss of 
confidence, etc. for work. These symptoms are dependent upon 
massive release of neurotransmitters like norepinephrine, dopamine, 
and glutamate. They possibly include neurotensin and neuro kinins too. 
The activity of most of above neurotransmitters is largely dependent 
upon release from the presynaptic terminals of neurons and ultimately 
intracellular calcium ion concentration built up through voltage-gated 
slow calcium channels [1]. Hence, calcium blockers in all probability 
must have a vital role to inhibit the release of the above 
neurotransmitters in the brain to control the symptoms [2].  
Current therapy for the above disorders is by the use of 
antidepressants of different types most common of which include 
Tricyclic Antidepressants (TCADs), Selective Serotonin Reuptake 
Inhibitors (SSRI) and sedatives as add-on therapy. TCADs like 
imipramine are associated with anticholinergic side effects and drug 
dependence while SSRI ones are having side effects of initial anxiety, 
the long onset of action, nausea, dysorganesmia and the rarely 
serotonin syndrome. Hence, due to the side effect profile of current 
drugs search for a better drug will be worth trying which is 
relatively safe and free from major side effects. 
Further, the neurotransmitter theory [3] for most of above neurotic 
disorders involves either excess release of excitatory neuro-
transmitters for an episode of morbid anxiety while same when 
depleted will cause up-regulation of adrenergic receptors in CNS 
with depression features. Sudden desensitization of beta receptors 
or role of some unknown inhibitory neurotransmitters (yet an 
unexplored area) can also be proposed for the sudden intense 
sadness or extreme low fee. Similarly, depression periods are 
associated with low levels of serotonin or norepinephrine with high 
levels of dopamine [4] which may be responsible for the impulsive 
behavior in the form of aggression and self-harm, even to the extent 
of suicidal attempts. Further, there may also be an imbalance of 
excitatory and inhibitory transmitters as evidenced by the use of 
benzodiazepine which act by enhanced activity of GABA (a major 
inhibitory neurotransmitter in brain [5-7]. Buspirone due to its 
presynaptic 5HT1A agonistic actions inhibits the release of above 
neurotransmitters, but it is a slow acting drug, requiring about 6-8 
wks to produce beneficial effects. Propranolol is mainly used for the 
control of peripheral manifestations of anxiety like tachycardia and 
tremors, but on the long term it itself produces depression. All above 
drugs are associated with marked side effects.  
Examples of neurotic disorders include anxiety neurosis, obsessive 
compulsive disorder (O. C. D), hysteria, social phobias, post-traumatic 
stress disorder (P. T. S. D) and endogenous depression, etc. 
Currently, used calcium channel blockers include nifedipine, 
amlodipine, nicardipine, diltiazem, verapamil, nimodipine, and 
nicardipine, etc. Calcium channel blockers have been used for 
various cardiovascular disorders like hypertension, myocardial 
ischemia, cardiac arrhythmias and peripheral vascular disease, etc 
[8]. Out of these nimodipine has shown beneficial effects in 
neurological disorders like cerebral stroke and migraine without 
any significant adverse effects on the cardiovascular system. Due to 
the high lipid solubility and relative safety profile, it created our 
interest to explore its potential use in neurotic disorders [8, 9]. 
Calcium channel blockers are working via voltage-gated calcium 
channels of various types [10, 11] which mainly include L, N, P/Q, R 
and T-subtypes. Out of these L-type of channels is mainly working in 
blood vessels and heart. N-type is working in neurons and is also 
responsible for the release of few endocrine hormones while T-type 
is mainly involved in neuronal activity. The functions of P/Q and R 
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subtypes are still undefined. However blockers are nonspecific in 
relation to the type of channel being involved. If calcium is responsible 
for the release of multiple neurotransmitters such as norepinephrine, 
glutamate, dopamine, etc. in the CNS, then blockers in all possibilities 
must have a vital role in prevention and treatment of various diseases 
associated with an excess of these transmitters like morbid anxiety and 
other psychiatric depression [12]. Nimodipine due to high lipid 
solubility, cerebral penetration and blocking action on slow calcium 
channels can be a potential target to treat neurotic disorders. At low 
doses, it has been shown to inhibit release of norepinephrine and 
dopamine. This may explain its anti-anxiety effects. Only very limited 
studies have been performed to evaluate above activities and prove its 
utility. Hence, more research work is worth doing [13]. 
MATERIALS AND METHODS 
Drugs 
Tab Serta (Sertraline 50 mg Intas pharma India), Tab Compose 
(Diazepam 10 mg Ranbaxy Pharmaceuticals, India) and Tab Nimodip 
(Nimodipine 30 mg-SUV Pharmaceuticals, India). In all the experiments 
drugs were given by intraperitoneal route except subacute intervention 
where sertraline was given by oral route. Drugs were purchased from 
the market through their authorized representatives. 
Animals 
Swiss albino mice (20-30 g) of either sex were procured from the 
central animal house, M. G. M. Medical College, Indore and 
acclimatized for a period of 7 d at room temperature (25±2 °C) and 
50±15% relative humidity. They were housed in a standard cage and 
maintained on standard pellets and water ad libitum. The animals 
were used as per standard animal handling guidelines. The study 
was carried out in the Department of Pharmacology, M. G. M. Medical 
College, Indore (M. P.) India. The study protocol was approved by 
the Institutional Animal Ethics Committee (IAEC) registered with 
CPCSEA (Reg. No. 709) on 26-8-2014.  
Methodology 
Anti-anxiety activity on EPM 
Principle 
EPM [14, 15] is the simplest method to evaluate the anti-anxiety 
property of various drugs. Exposure of the animals to novel maze 
alley evokes an approach-avoidance conflict which is stronger in the 
open arms as compared to enclosed space. Rodents have a version 
for high and open space and prefer enclosed arms and therefore 
spend a greater period of time in enclosed arms [16, 17]. When the 
animals enter open arm, they freeze, become immobile, defecate and 
show fear like movements. The plasma cortisol level is also reported 
to be increased, as a true reflection of anxiety. 
Equipment 
The elevated plus-maze was introduced by Pellow [18] for rats and 
by Listetil for mice respectively. The EPM apparatus consisted of two 
open arms (30 x 5 cm) and two closed arms (30 x 5 x 20 cm) 
emanating from a common central platform (5 x 5 cm). The two 
parts of identical arms are opposite (at a right angle) to each other. 
The entire apparatus is elevated to a height of 50 cm above the floor 
level. The latest y-maze apparatus consists of three arms where all 
the arms are closed; one arm is illuminated while two arms are non-
illuminated, but the current is passed at the floor. Each arm entry is 
compared before and after giving the test drug. Entries in each arm 
are counted by electronic counters.  
Method 
Total no of animals 24 were divided into four groups (n=6). Group I-
Distilled water (0.2 ml), Group II-Diazepam 2 mg/kg, Group III-
Nimodipine 2.5 mg/kg, Group IV-Nimodipine 2.5 mg/kg and 
diazepam 2 mg/kg combination. The animals were exposed to house 
caging for ten days with adequate food, water, with proper day and 
night 12 hourly cycles. Proper acclimatization of the animals was 
done for the place and handlers where the experiment was to be 
performed. On the eleventh day after the adequate adaptation, mice 
received the treatment at 11.30 am a half hour before the start of the 
session between 12 noon-1pm. At the beginning of the session, a 
mouse was placed at the center of the maze, its head facing the 
closed arms and total entries in different arms was recorded. An 
entry was defined as the presence of all four paws in the arm. The 
EPM was carefully wiped, with 10 % of ethanol after each trial, to 
eliminate the possible bias due to the order of the previous animal. 
The entries were recorded automatically by the electronic recorder 
in different arms for ten minutes. 
Antidepressant activity 
Method 
TST is also a simple apparatus to study the antidepressant activity of 
different drugs. Animals are suspended inverted on the wire by 
adhesive tape fixed to the tail. The height of the wire is 50 cm above 
the study table. Mobility is recorded for 300 s. There are periods of 
alternate mobility and immobility. Antidepressant activity is reflected 
by a decrease in the time of immobilization when the rodents are 
suspended inverted from their tail. Both acute and sub-acute (15 d 
treatment) studies were carried out. Here 24 mice were divided into 
four groups of (n=6) and treated as follows-Group I-Distilled water 
(0.2 ml). Group II-Sertraline 2 mg/kg. Group III-Nimodipine 2.5 mg/kg 
Group IV-Nimodipine 5 mg/kg and Group V-Nimodipine 2.5 mg/kg 
and Sertraline 2 mg/kg. Groups were similar in both the acute and 
subacute studies (sertraline which was given orally for 15 d). 
Effects on duration of sleep 
Method 
The hypnotic effect is seen on phenobarbitone induced sleeping time. 
The loss of writing reflex is considered as a time of onset of sleep while 
the recovery is calculated by regaining and maintaining of the correct 
posture. Total animals 24 were divided into four groups of (n=6) each 
and treated as follows. Group I-Distilled water 0.2 ml. Group-II-
Phenobarbitone 35 mg/kg, Group III-Nimodipine 5 mg/kg and Group IV-
combination of Nimodipine and Phenobarbitone in above doses. 
RESULTS 
(1) Nimodipine at a dose of 2.5 mg/kg body wt has shown a 
moderate anti-anxiety effect. The percentage ratio of entry into open 
arms/closed arms was significantly higher as compared to the 
control even after acclimatization for 10 d implying moderate anti-
anxiety effects. The ratio was further increased when it was 
combined with diazepam, having nearly addictive actions. However 
same cannot be said with confidence about anti-anxiety activity at 5 
mg/kg since (i) total entries were reduced (ii) animals were sluggish 
on plus-maze due to CNS depression and (iii) TST has shown 
depression due to prolongation time of immobilization (still anti-
anxiety effects can be expected due to calming property). (table 1). 
 
Table 1: Effects of nimodipine on elevated plus maze test 
Groups Dose (i. p.) mg/kg Mean ratio of open/closed arms in %±SEM Inference 
Control 0.2 ml Distilled water  32.49±2.02  
Diazepam 2  51.50±1.240a,b, Known anxiolytic. 
Nimodipine 2.5 44.9±1.029a,b,c, May have anti-anxiety property. 
Nimodipine+diazepam 2.5+2 58.60±0.97a,c Improved anti anxiety effect of 
diazepam. 
Result-ANOVA with multiple tukey’s tests. df = 3,12, n=5, ap<0.05 as compared to control, bp<0.05as compared combination of diazepam and 
nimodipine, cp<0.05as compared to diazepam, (2) Antidepressant activity was also seen at a dose of 2.5 mg/kg, which was changed to depressive 
behavior at high dose of 5 mg/kg as indicated by prolonged time of immobilization on TST (table2-3). 
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Table 2: Effects of single dose of nimodipine on tail suspension test 
Gross up Dose (i. p) 
mg/kg 
Time of immobilization (out of 300 s) 
(mean±SEM) 
Inference 
Control Distilled water 0.2 ml 209.2±3.11 Control 
Sertraline 5 204.6±6.161 No change on acute doses. 
Nimodipine 2.5 188.00±2.23a Anti-depressant activity. 
Nimodipine 5 228.80±5.82a. Significant depressant activity. 
Nimodipine+sertraline 2.5+5 200.80±3.00 The antidepressant action of acute nimodipine, but 
no antidepressant activity of acute sertraline. 
Nimodipine+sertraline 5+5 224.40±4.45a The depressant activity of higher dose of 
nimodipine having opposing effects on those of 
acute sertraline. 
Results-ANOVA with multiple Tukey's tests, d f= 4, 24, ap<0.05as compared to control. 
 
Table 3: Effects of nimodipine on subacute (14 d) sertraline on tail suspension test 
Group Dose (i. p) 
mg/kg 
Time of Immobilization (out of 
300 s) (mean±SEM) 
Inference 
Control Distilled water. 0.2 ml  209±7.88 - 
Sertraline 5 98.4±8.95a Antidepressant 
Nimodipine 2.5 180.8±8.79 a,b Antidepressant but less than sertraline. 
Nimodipine+sertraline  2.5+5 84.8±3.49 a,c Slight improvement in anti-depressant activity of 
sertraline. 
Result-ANOVA test was applied. p-value of the study= 0.000 (among different groups) d f=3,17., ap<0.05 as compared to control. bp<0.05 as 
compared to sertraline, cp<0.05 as compared to nimodipine 2.5 mg/kg. 
 
Effect of nimodipine on subacute sertraline administration is of 
potentiation of the antidepressant activity of sertraline. Nimodipine 
itself has antidepressant activity at a dose of 2.5 mg/kg though it is 
inferior to that of sertraline. 
(3) There was no effect of 2.5 mg/kg of nimodipine, but at 5 mg/kg it 
significantly increased the duration of sleep produced by 
phenobarbitone (table-4). Similarly, nimodipine itself could not 
induce sleep in mice. 
 
Table 4: The effects of nimodipine on phenobarbitone induced sleeping time 
Groups Dose (n=6) mg/kg Mean Duration of sleep in min.±SEM Inference 
Control Distilled water  0.2 ml _  
Phenobarbitone 35 70.8±1.77 a,b Known sedative 
Nimodipine 2.5 _ No sedative action 
Nimodipine+phenobarbitone  35+2.5 76.4±2.315a,b,c Nimodipine prolonged the action 
ANOVA with post hoc multiple Tukey's test applied. df= 3,16., ap-value<0.05 as compared to control., bp-value<0.05 as compared to nimodipine 2.5 mg/kg. 
 
DISCUSSION 
Antianxiety and antidepressant activity 
Nimodipine may be an example of a drug having selective inhibition of 
release of multiple neurotransmitters at different doses. At a dose of 
2.5 mg/kg, there may be net lowering of few excitatory 
neurotransmitters like norepinephrine, glutamate and tachykinins, etc. 
without modulation (inhibition) of serotonin to produce anti-anxiety 
and antidepressant behavior as compared to control group. There was 
no change on the activity of acute sertraline group, however on 
subacute intervention; it potentiated the antidepressant activity of 
sertraline. This could be due to the down-regulation of adrenergic 
receptors brought by standard drug over a period of 14 d. Further, we 
have to hypothesize about the role of multiple inhibitory transmitters 
(area to be yet explored and searched) which bring about sudden 
depression or down feeling of mood. There may be a block of above 
unknown neurotransmitters to show antidepressant activity. 
The basis of anxiety and depression is currently believed to be due 
to a nice interaction between excitatory neurotransmitters like 
norepinephrine (NE) and glutamate v/s inhibitory transmitters like 
gamma amino butyric acid (GABA). A very good explanation has 
been given about anxiety [3]. During attacks of sudden anger either 
there is the excessive release of norepinephrine or probably 
dopamine too at the synaptic junction from presynaptic vesicles or 
there is up-regulation of beta receptors at postsynaptic neurons. 
Nimodipine by decreasing intracellular calcium load may be able to 
reduce the firing of neurons and thus may control the release of 
different involved transmitters to control symptoms. TCADs are 
working on pre and postsynaptic neurons, and they prevent 
reuptake of serotonin and norepinephrine with consequent down-
regulation of beta and serotonin receptors over a period of time. 
SSRI drugs inhibit uptake of serotonin only. On long-term changes in 
the form of modifications on genes [19-21] and neuroplasticity [3] too 
have been postulated. Depression too is presently considered a 
neurodegenerative disorder due to constant release of glutamate 
during episodes of anxiety with associated neuronal toxicity. While an 
antidepressant group of drugs by lowering anxiety may reduce 
degeneration and improve gene related neuroplasticity over the 
course of therapy. We propose that nimodipine by lowering 
neurotransmitter turnover may prevent or reduce the rate of neuronal 
degeneration to some extent to help the patients in the long term. In 
addition to treatment of depression, low dose of antidepressant drugs 
are often required for treatment of anxiety symptoms too. The 
mechanism for the actions of antidepressants in anxiety possibly 
involves the presynaptic autoreceptors which by inhibitory actions 
decrease the release during episodes of severe anxiety or by 
postsynaptic actions cause down-regulation of adrenergic receptors. 
The depression has been suggested due to up-regulation of 
adrenergic receptors with consequent secondary changes in 
neurons [3]. The clinical evidence for above observations has been 
depression caused due to constant use of beta blockers and adrenergic 
neuron blockers with up-regulation of adrenergic receptors leading to 
sadness and depressive mood. Though propranolol is used for acute 
treatment of anxiety tremors, it is mainly used for lowering the 
peripheral manifestations in acute morbid anxiety only.  
Hence as soon as the severity of anxiety is controlled, propranolol is 
stopped, and the patient is shifted to various antidepressant drugs. 
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Nimodipine by slightly lowering blood pressure will also take care of 
peripheral manifestations of anxiety and depression. Further, the 
advantage of nimodipine over propranolol may be due to its 
additional antidepressant property even at sub-therapeutic doses. 
Similarly, an advantage over diazepam may be in the form of no 
addiction and drowsiness. Similarly, the edge over buspirone may be 
due to its immediate onset. The biological sites in the brain for anxiety 
are organs like the hippocampus and prefrontal cortex (PFC) [22, 23]. 
Electroconvulsive therapy (ECT) has been shown to cause a massive 
release of amine transmitters with concomitant downregulation of 
receptors. This can explain ECT treatment for major depression. Like 
beta blockers, which are the only antagonist to catecholamines in the 
periphery, our investigational drug nimodipine in low doses can 
probably decrease the release of norepinephrine, glutamate and yet 
unknown multiple excitatory neurotransmitters in CNS to relieve 
anxiety. They have simply calming effect without the drowsiness which 
may be very advantageous in heavy machinery workers or heavy motor 
drivers on the road. Later expected depression will also be less since 
neurotransmitters will be stored in adequate amount in vesicles and 
constantly released in the synaptic cleft to elevate mood and also 
secondary to downregulation of serotonin and adrenergic receptors. 
Thus, our suggestions may favor for nimodipine for treating morbid 
anxiety with the advantage of no sedation in highly skilled persons, 
though it has been shown to prolong the sleeping time induced by 
phenobarbital. Our findings are matched to those of French study who 
have shown the anti-anxiety potential of nimodipine [24]. 
Sedative property  
Further the animals were fully awake indicating no sedative effect 
(no calming property), but at higher dose of 5 mg/kg of nimodipine 
it was found to produce moderate CNS sedation shown by lower 
spontaneous motor activity, significantly reduced total entries in all 
the arms (though the proportion of entries in open arms was still 
higher as compared to closed arms-still doubtful antianxiety effects 
maintained) and also by prolonging sleep time. This could be a 
calming effect due to further inhibition of the release of some more 
excitatory neurotransmitters. At the same dose of 5 mg/kg, it showed 
depression activity by prolonged time of immobilization. This could be 
due to the simultaneous inhibition of serotonin release too from nerve 
endings. The depression was also seen with the certain group 
combination, and it was able to reverse the antidepressant activity of 
certain. The effect may be due to complete block of serotonin, in spite 
of down-regulation of adrenergic receptors. The Same dose probably 
also inhibits dopamine, which can further explain the antipsychotic 
activity (along with inhibition of serotonin release too) which is seen 
at doses of 5 mg-10 mg/kg dose in mice [25]. 
CONCLUSION 
The drug nimodipine has shown promising results for its 
antidepressant, anti-anxiety and calming activities in preclinical 
studies in albino mice. The drug can be tried as adding on therapy with 
routine drugs for the above disorders without significant side effects 
on the human system. However, further clinical trials have to be 
conducted to establish its utility. The half-life of nimodipine given by 
intraperitoneal route is 1.51 h while oral bioavailability is only10 % 
which may explain the inconstant results obtained till date in previous 
studies. If sustained release preparation is formulated for use by an 
oral/parenteral route which can maintain desired concentrations, it 
may be an additional tool for the treatment of neurotic disorders.  
ACKNOWLEDGEMENT 
We are thankful to the dean and staff of the department of pharmacology 
for the co-operation and help required during the experimental work.  
CONFLICT OF INTERESTS  
Declared none 
REFERENCES 
1. Rang HP, Dale MM. Textbook of pharmacology. 7thEdition. 
Churchill Livingstone Elsevier, London [UK]; 2012. p. 265-85. 
2. Sharma HL, Sharma KK. Principles of pharmacology. 2ndEdition. 
Paras Publications, Hyderabad India; 2012. 
3. Gulley LR, Nemeroff CB. Biological basis of anxiety depression. J 
Clin Psychiatry 1993;54 Suppl I:16-9. 
4. Dongju. http://www.ncbi.nlm.nih.gov/pubmed/?term=Seo% 
20D%5Bauth%5D S Patrick CJ, Kennealy PJ. http:// 
www.ncbi.nlm.nih.gov/ pubmed/?term=Kennealy% 20PJ% 
5Bauth%5D>Role of Serotonin and Dopamine System 
Interactions in the Neurobiology of Impulsive Aggression and 
its comorbidity with other clinical disorders. Aggress Violent 
Behav 2008;13:383-95. 
5. Baldessarani RJ, Tarzai FI. The pharmacological basis of 
therapeutics. 12thEdition. McGraw-Hill New York; 2011. p. 461-80. 
6. James BJ, Sadock VA. Schizophrenia in the synopsis of 
psychiatry. 10thedition. Behavioral Sciences/clinical psychiatry. 
Lippincott Williams and Wilkins [Philadelphia]; 2007. 
7. Nyati P. Pharmacology SEED. 2nd edition. Global media, India; 2011. 
8. Shrivastava SK. A complete textbook of medical pharmacology. 
1st edition. The avichal publishing company, India; 2012. 
9. Lacinova L. http://www.ncbi.nlm.nih.gov/Pubmed/? term= 
Lacinov%C3%A1%20L%5BAuthor%5D&cauthor=true&cautho
r_uid=16096350>. Voltage-dependent calcium channels. Gen 
Physiol Biophys 2005;24 Suppl 1:1-78. 
10. Schwatz A. Molecular and cellular effects of calcium channel 
blockers. Am J Cardiol 1992;70:6F-8F. 
11. Tsien RW, Lipscombe D, Madison, Bley DV. Multiple types of 
neuronal calcium channels & their selective modulation. 
Trends Neurosci 1988;24 Suppl 1:431-8. 
12. Goodnick PJ. The use of nimodipine in the treatment of mood 
disorders. Bipolar Disord 2000;2:165-73. 
13. Rataboli P, Garg A, Muchandi K. Antidepressant effect of low 
dose nimodipine in the mouse behavior despair model. 
Internet J Pharmacol 2009;8:1. 
14. Vogel HG. Antidepressant activity on the elevated plus maze in 
drug discovery and evaluation pharmacological assays. 2nd 
Edition. Springer-Verlag, Berlin [Heidelberg]; 2002. 
15. Kaul PN, Kulkarni SK. New drug metabolism inhibitor of marine 
origin. J Pharm Sci 1979;67:1293-6. 
16. Pellow S, Johnston AL, File SE. Selective agonists and 
antagonists for 5-hydroxytryptamine receptor subtypes and 
interaction with yohimbine and FG 7142 using the elevated 
plus-maze test in the rat. J Pharmacol 1987;39:917-28.  
17. Sharma AC, Kulkarni SK. Evaluation of learning and memory 
mechanisms employing elevated plus-maze in rats and mice. 
Prog Neuro-Psychopharmacol Biol Psychiatry 1992;16:117-25. 
18. Pellow S, Chopin P, File SE, Briley M. Validation of open: closed 
arm entries in an elevated plus-maze as a measure of anxiety in 
the rat. J Neurosci Methods 1985;14:149-67. 
19. Ongür D, Heckers<http://www.pubfacts.com/author/ Stephan+ 
Heckers>S: "A role for glia in the action of electroconvulsive 
therapy". Harv Rev Psychiatry 2004;12 Suppl 5:253-62. 
20. Duman RS. Depression: a case of neuronal life and death? Biol 
Psychiatry 2004;56 Suppl 3:140-5. 
21. Duman CH<http://www.ncbi.nlm.nih.gov/Pubmed/? term= 
Duman%20CH%5BAuthor%5D&cauthor=true&cauthor_uid=16
594263>, Duman RS<http://www. ncbi.nlm. nih.gov/ Pubmed/? 
term=Duman%20RS%5BAuthor%5D&cauthor=true&cauthor_
uid=16594263>: Neurobiology and treatment of anxiety. Signal 
transduction and neural plasticity. Handy Exp Pharmacol 
2005;169:305-34. 
22. Warner-Schmidt JL, Duman RS. Hippocampal neurogenesis 
opposing effects of stress and antidepressant treatment. 
Hippocampus 2006;16 Suppl 3:239-49. 
23. Less S. The relationship of anxiety to depression. Am J 
Psychother 1982;36:332-49. 
24. Biala Gryzyna, Kruk Marta. Polish academy of sciences. Pologne 
2007;59:636-44. 
25. Tanwani H, Pandey SP, Atal S, Nyati P. Evaluation of the anti-
psychotic effect of nimodipine using methylphenidate as a 
model to induce psychosis in albino mice. Int J Basic Clin 
Pharmacol 2015;4:1047-53. 
 
